Accession Number: | 0001209191-20-008006 |
Date: | 2020-02-06 |
Issuer: | ROCKET PHARMACEUTICALS, INC. (RCKT) |
Original Submission Date: |
ALAM KAMRAN
C/O ROCKET PHARMACEUTICALS, INC.
350 FIFTH AVENUE, SUITE 7530
NEW YORK, NY 10118
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 22.72 | 2020-02-06 | deemed execution date | A | 25,000 (a) | 2030-02-06 | common stock 25,000 | $22.72 | 25,000 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 23.89 | 2020-02-10 | deemed execution date | A | 3,000 (a) | 2030-02-10 | common stock 3,000 | $23.89 | 3,000 | direct |
ID | footnote |
---|---|
f1 | this option represents a right to purchase a total of 25,000 shares of the issuer's common stock, one-third of which will become fully vested and exercisable on february 6, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the issuer. |
f2 | this option represents a right to purchase a total of 3,000 shares of the issuer's common stock, one-third of which will become fully vested and exercisable on february 10, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the issuer. |